Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Rhinomed.
RELATED STOCKHEAD STORIES
News
Top 10 at 11: There’s movement on the market, but not much news to explain why
News
Rise and Shine: Everything you need to know before the ASX opens
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX traders happy to take the profit after surprise CPI windfall
News
ASX Earnings Wrap: Harvey Norman profit slumps, competitor Joyce Corp jumps
Health & Biotech
Weed Week: ‘Welcome to the psychedelic 2020s!’ as market holds breath on key US approval
Health & Biotech
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Experts
CRITERION: Gains without pains? Maybe tackle these sporting injury stocks instead
Experts
Dr Boreham’s Crucible: It’s been a 10-year snooze but Rhinomed looks like it’s ready to jump out of bed
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Health & Biotech
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
News
ASX Small Cap Lunch Wrap: Who’s really feeling bullish today?
Health & Biotech
ASX Health Stocks: ResApp skyrockets 25% after getting buyout offer from US giant Pfizer
Experts
ScoPo’s Powerplays: Green shoots appear among smaller ASX health stocks
News
Closing Bell: International Graphite climbs 97.5% in its first session, all else is dust
Health & Biotech
ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada
Health & Biotech
